384 related articles for article (PubMed ID: 32903563)
1. Engineering CAR T Cells to Target the HIV Reservoir.
Mu W; Carrillo MA; Kitchen SG
Front Cell Infect Microbiol; 2020; 10():410. PubMed ID: 32903563
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
3. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
Covino DA; Desimio MG; Doria M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
[TBL] [Abstract][Full Text] [Related]
4. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
5. Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells.
Ruiz A; Blanch-Lombarte O; Jimenez-Moyano E; Ouchi D; Mothe B; Peña R; Galvez C; Genescà M; Martinez-Picado J; Goulder P; Barnard R; Howell B; Clotet B; Prado JG
Front Immunol; 2018; 9():3162. PubMed ID: 30723480
[TBL] [Abstract][Full Text] [Related]
6. The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation.
Macedo AB; Levinger C; Nguyen BN; Richard J; Gupta M; Cruz CRY; Finzi A; Chiappinelli KB; Crandall KA; Bosque A
J Virol; 2022 Aug; 96(15):e0037222. PubMed ID: 35867565
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
[TBL] [Abstract][Full Text] [Related]
8. Which therapeutic strategy will achieve a cure for HIV-1?
Cillo AR; Mellors JW
Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
[TBL] [Abstract][Full Text] [Related]
9. Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill.
Kristoff J; Rinaldo CR; Mailliard RB
Viruses; 2019 Dec; 12(1):. PubMed ID: 31905690
[TBL] [Abstract][Full Text] [Related]
10. Nanodepots Encapsulating a Latency Reversing Agent and Broadly Neutralizing Antibody Enhance Natural Killer Cell Cytotoxicity Against an in vitro Model of Latent HIV.
Ghofrani J; Bowen A; Chen J; Balakrishnan PB; Powell AB; Cherukula K; Cruz CRY; Jones RB; Lynch RM; Sweeney EE; Fernandes R
Int J Nanomedicine; 2023; 18():4055-4066. PubMed ID: 37520301
[TBL] [Abstract][Full Text] [Related]
11. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
12. VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies.
Puertas MC; Bayón-Gil Á; Garcia-Guerrero MC; Salgado M; Urrea V; Morón-López S; Peña R; Jiménez-Moyano E; Clotet B; Prado JG; Martinez-Picado J
mBio; 2021 Jun; 12(3):e0056021. PubMed ID: 34154408
[TBL] [Abstract][Full Text] [Related]
13. HIV latency reversal agents: A potential path for functional cure?
Lopes JR; Chiba DE; Dos Santos JL
Eur J Med Chem; 2021 Mar; 213():113213. PubMed ID: 33540228
[TBL] [Abstract][Full Text] [Related]
14. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
Gupta V; Dixit NM
PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
[TBL] [Abstract][Full Text] [Related]
15. Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir
York J; Gowrishankar K; Micklethwaite K; Palmer S; Cunningham AL; Nasr N
Front Immunol; 2022; 13():873701. PubMed ID: 35572509
[TBL] [Abstract][Full Text] [Related]
16. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
17. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
[TBL] [Abstract][Full Text] [Related]
18. Potential of the NKG2D/NKG2DL Axis in NK Cell-Mediated Clearance of the HIV-1 Reservoir.
Desimio MG; Covino DA; Doria M
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514330
[TBL] [Abstract][Full Text] [Related]
19. Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs.
Sadowski I; Hashemi FB
Cell Mol Life Sci; 2019 Sep; 76(18):3583-3600. PubMed ID: 31129856
[TBL] [Abstract][Full Text] [Related]
20. Potential Utility of Natural Killer Cells for Eliminating Cells Harboring Reactivated Latent HIV-1 Following the Removal of CD8
Khoury G; Kulpa DA; Parsons MS
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
